AI Verdict
KURA has stronger fundamentals based on our AI analysis.
KURA vs KTB Fundamental Comparison
| Metric | KURA | KTB |
|---|---|---|
| Revenue | $67.5M | $3.2B |
| Net Income | $-278.7M | $227.5M |
| Net Margin | -412.9% | 7.2% |
| ROE | -160.0% | 40.3% |
| ROA | -37.7% | 8.8% |
| Current Ratio | 6.06x | 1.82x |
| Debt/Equity | 0.06x | 2.02x |
| EPS | $-3.18 | $4.05 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KURA vs KTB: Frequently Asked Questions
Is KURA or KTB a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), KURA has stronger fundamentals. KURA is rated HOLD (72% confidence) while KTB is rated HOLD (68% confidence). This is not investment advice.
How does KURA compare to KTB fundamentally?
Kura Oncology, Inc. has ROE of -160.0% vs Kontoor Brands, Inc.'s 40.3%. Net margins are -412.9% vs 7.2% respectively.
Which stock pays higher dividends, KURA or KTB?
KURA has a dividend yield of N/A or no dividend while KTB has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KURA or KTB for long term?
For long-term investing, consider that KURA has HOLD rating with 72% confidence, while KTB has HOLD rating with 68% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KURA vs KTB?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KURA vs KTB, the AI consensus favors KURA based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.